Top Stories
Ivermectin + Mebendazole: Groundbreaking Study Reports 84.4% Clinical Benefit Rate in Cancer Patients
A newly released observational analysis found that 84.4% of cancer patients treated off-label with a compounded combination of Ivermectin and Mebendazole experienced a clinical benefit.
Read more at BREITBART ›
Read the full story at
BREITBART
The Gadsden Report aggregates and summarises headlines. The reporting above belongs to BREITBART, and the link opens their page. This page exists so readers can find, share, and discuss the story here.